JP5975983B2 - 固形腫瘍を処置するための方法 - Google Patents

固形腫瘍を処置するための方法 Download PDF

Info

Publication number
JP5975983B2
JP5975983B2 JP2013505156A JP2013505156A JP5975983B2 JP 5975983 B2 JP5975983 B2 JP 5975983B2 JP 2013505156 A JP2013505156 A JP 2013505156A JP 2013505156 A JP2013505156 A JP 2013505156A JP 5975983 B2 JP5975983 B2 JP 5975983B2
Authority
JP
Japan
Prior art keywords
antigen
subject
prostate cancer
region
multimeric ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013505156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525305A5 (cg-RX-API-DMAC10.html
JP2013525305A (ja
Inventor
ケビン スローウィン，
ケビン スローウィン，
デイビッド スペンサー，
デイビッド スペンサー，
ナタリア ラプティーバ，
ナタリア ラプティーバ，
Original Assignee
ベリカム ファーマシューティカルズ， インコーポレイテッド
ベリカム ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベリカム ファーマシューティカルズ， インコーポレイテッド, ベリカム ファーマシューティカルズ， インコーポレイテッド filed Critical ベリカム ファーマシューティカルズ， インコーポレイテッド
Publication of JP2013525305A publication Critical patent/JP2013525305A/ja
Publication of JP2013525305A5 publication Critical patent/JP2013525305A5/ja
Application granted granted Critical
Publication of JP5975983B2 publication Critical patent/JP5975983B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
JP2013505156A 2010-04-16 2011-04-14 固形腫瘍を処置するための方法 Expired - Fee Related JP5975983B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32512710P 2010-04-16 2010-04-16
US61/325,127 2010-04-16
US35176010P 2010-06-04 2010-06-04
US61/351,760 2010-06-04
US201161442582P 2011-02-14 2011-02-14
US61/442,582 2011-02-14
PCT/US2011/032572 WO2011130566A2 (en) 2010-04-16 2011-04-14 Method for treating solid tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016060361A Division JP2016117770A (ja) 2010-04-16 2016-03-24 固形腫瘍を処置するための方法

Publications (3)

Publication Number Publication Date
JP2013525305A JP2013525305A (ja) 2013-06-20
JP2013525305A5 JP2013525305A5 (cg-RX-API-DMAC10.html) 2014-05-01
JP5975983B2 true JP5975983B2 (ja) 2016-08-23

Family

ID=44799326

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013505156A Expired - Fee Related JP5975983B2 (ja) 2010-04-16 2011-04-14 固形腫瘍を処置するための方法
JP2016060361A Withdrawn JP2016117770A (ja) 2010-04-16 2016-03-24 固形腫瘍を処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016060361A Withdrawn JP2016117770A (ja) 2010-04-16 2016-03-24 固形腫瘍を処置するための方法

Country Status (6)

Country Link
US (2) US20110287038A1 (cg-RX-API-DMAC10.html)
EP (1) EP2558109A4 (cg-RX-API-DMAC10.html)
JP (2) JP5975983B2 (cg-RX-API-DMAC10.html)
AU (1) AU2011239569B2 (cg-RX-API-DMAC10.html)
CA (1) CA2795947A1 (cg-RX-API-DMAC10.html)
WO (1) WO2011130566A2 (cg-RX-API-DMAC10.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516320C (en) * 2003-02-18 2015-05-26 Kevin Slawin Induced activation in dendritic cells
US8691210B2 (en) * 2006-10-19 2014-04-08 David M Spencer Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
AU2009292996B2 (en) 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
AU2010310986A1 (en) 2009-10-29 2012-06-14 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US20130143237A1 (en) 2011-11-29 2013-06-06 Genentech, Inc. Compositions and methods for prostate cancer analysis
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2905352A1 (en) * 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP2970372B1 (en) 2013-03-15 2020-09-30 Celgene Corporation Modified t lymphocytes
WO2014144731A2 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same
MX428954B (es) * 2013-03-15 2025-11-13 Univ Pennsylvania Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana.
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
JP6496472B2 (ja) * 2013-07-03 2019-04-03 三菱重工機械システム株式会社 車載器、及びスプーフィング検知方法
EP3104866A4 (en) * 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
EP2940136A1 (en) * 2014-04-30 2015-11-04 QIAGEN GmbH Method for isolating poly(A) nucleic acids
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
WO2016071758A1 (en) 2014-11-03 2016-05-12 Leiden University Medical Center T cell receptors directed against bob1 and uses thereof
EP3215521B1 (en) * 2014-11-06 2025-10-08 University of Maryland, Baltimore Cd8 and t cell receptor variants and methods of using same in modulating immune cell responses
EP3234145B1 (en) * 2014-12-15 2019-06-05 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US20190008897A1 (en) * 2015-07-22 2019-01-10 University Of Washington Compositions and methods for producing pro-inflammatory macrophages
JP7032304B2 (ja) 2015-07-28 2022-03-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用
CA3002685A1 (en) * 2015-10-30 2017-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of her2-expressing solid tumors
JP6904667B2 (ja) 2016-06-14 2021-07-21 日本光電工業株式会社 バイトブロック及びガスセンサキット
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
EP3621988A1 (en) 2017-05-09 2020-03-18 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
EP3675902A4 (en) 2017-08-28 2021-06-23 Board of Trustees of Michigan State University COMPOSITIONS AND METHODS OF TREATMENT OF CANCER AND INFECTION USING BACTERIOPHAGE AND THEIR MUTANTS
BR112020005938A2 (pt) 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
AU2018378955A1 (en) 2017-12-08 2020-06-18 Bellicum Pharmaceuticals, Inc. Methods for enhancing and maintaining CAR-T cell efficacy
WO2019126344A1 (en) 2017-12-20 2019-06-27 Bellicum Pharmaceuticals, Inc. Multimeric piperidine derivatives
US20220000921A1 (en) * 2018-11-20 2022-01-06 Innovative Cellular Therapeutics Holdings, Ltd. Modified Cell Expressing Therapeutic Agent and Uses thereof
US12702708B2 (en) 2019-08-21 2026-08-11 Innovative Cellular Therapeutics Holdings, Ltd. Presenting cell and use thereof in cell therapy
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
MX2022007107A (es) * 2019-12-11 2022-11-14 Myeloid Therapeutics Inc Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas.
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CA3162074A1 (en) * 2020-01-10 2021-07-15 Joseph HORVATINOVICH Methods of treating tumors
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
EP4161536A4 (en) 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
KR20240013094A (ko) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
CA2516320C (en) * 2003-02-18 2015-05-26 Kevin Slawin Induced activation in dendritic cells
JP2007511507A (ja) * 2003-11-14 2007-05-10 ジェンベク、インコーポレイティッド 癌を処置するための治療レジメン
US8691210B2 (en) * 2006-10-19 2014-04-08 David M Spencer Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
US8236318B2 (en) * 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
AU2009221915A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
WO2009151503A2 (en) * 2008-04-10 2009-12-17 University Of Florida Research Foundation, Inc. Compositions and methods for the treatment of a neoplasia
AU2009292996B2 (en) * 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters

Also Published As

Publication number Publication date
AU2011239569B2 (en) 2014-07-24
EP2558109A4 (en) 2014-09-24
EP2558109A2 (en) 2013-02-20
WO2011130566A3 (en) 2011-12-29
US20140023647A1 (en) 2014-01-23
US20110287038A1 (en) 2011-11-24
WO2011130566A2 (en) 2011-10-20
JP2013525305A (ja) 2013-06-20
JP2016117770A (ja) 2016-06-30
AU2011239569A1 (en) 2012-10-25
CA2795947A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
AU2011239569B2 (en) Method for treating solid tumors
US20240124552A1 (en) Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
JP7579726B2 (ja) メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用
JP2024056940A (ja) 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法
AU2014202528B2 (en) Generating an immune response by inducing CD40 and pattern recognition receptors
JP2017532018A (ja) ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激
AU2014253529A1 (en) Method for treating solid tumors
HK1245637A1 (en) Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
HK1249424B (en) T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
HK1159160A (en) Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
HK1159160B (en) Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160324

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160511

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160623

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160719

R150 Certificate of patent or registration of utility model

Ref document number: 5975983

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees